Investment
Features
FeesSafety
Academy
More
Pluang+

Compare Beyond Meat Inc (BYND) vs Invesco Ltd. (IVZ) Price & Performance

Beyond Meat IncTrade
Invesco Ltd.Trade

Price performance (Past 24H)

Key statistics

Beyond Meat Inc vs Invesco Ltd. — how do they compare? Beyond Meat Inc trades at $0.64 (market cap $320.23M), while Invesco Ltd. trades at $30.42 (market cap $12.74B). The key difference: Invesco Ltd. is far larger — about 39.8× Beyond Meat Inc's market cap, and Invesco Ltd. pays a 2.99% dividend while Beyond Meat Inc pays none. Which is the better fit depends on your goals.

BYNDIVZ
Market Cap
$320.23M$12.74B
Sector
Consumer StaplesFinancials
52-Week High
$4.28$29.44
52-Week Low
$0.52$16.74
Enterprise Value
$630.23M$22.98B
Dividend Yield
2.99%

Aura AI Summary

Signals from Pluang's Aura AI — not financial advice

Beyond Meat Inc

BYND trades at $0.63, down 4.15% today, reflecting persistent bearish sentiment amid declining revenues and negative cash flow from operations. The stock shows technical weakness with moving averages signaling bearish momentum, though oversold RSI conditions suggest potential for near-term bounce. Recent earnings show mixed results with Q1 2026 beating expectations but Q4 2025 and Q3 2025 missing estimates. The company continues expansion efforts with new product launches including Beyond Steak Filet and protein beverages.

Investment outlook remains challenging with 57% analyst sell ratings and negative operating cash flow of $145M in 2025. While valuation metrics appear attractive with P/S of 0.65 and EV/EBITDA of 2.08, ongoing revenue declines and reliance on financing activities for liquidity pose significant risks. The turnaround strategy through product diversification faces execution challenges in a competitive plant-based protein market.

Invesco Ltd.

Invesco (IVZ) trades at $28.4, down 2.0% on the day, with a bullish technical signal driven by moving averages. The company reported mixed earnings, beating in Q3 and Q4 2025 but missing in Q1 2026, while revenue grew to $6.38B in 2025. Analyst consensus is a Buy with a $30.50 price target, and recent news highlights upgrades and strong momentum.

The outlook is cautiously optimistic given analyst support and improving cash flow, but risks include negative net income margins and competitive pressures in asset management. Upside hinges on earnings recovery and AUM growth, while macroeconomic volatility remains a headwind.

Returns comparison

Trailing returns across standard periods

About Beyond Meat Inc

Beyond Meat is a provider of plant-based meats, such as burgers, sausage, ground beef, and chicken. Unlike other vegetarian products, Beyond Meat seeks to replicate the look, cook, and taste of meat, is targeted to omnivores and vegetarians alike, and is sold in the meat case. The products are widely available across the U.S. and Canada and in 83 additional countries as well. International revenue represented 31% of 2021 sales. The firm's products are available in retail stores and the food-service channel. In 2019, before the pandemic struck, sales were evenly split between these two channels, although mix stood at 70% retail/30% food service in 2021. We think the recovery from the crisis and new deals with McDonald's and Yum Brands will return food-service sales to nearly 50% in time.

Read more on BYND

About Invesco Ltd.

Invesco provides investment-management services to retail (65% of managed assets) and institutional (35%) clients. At the end of August 2022, the firm had $1.416 trillion in assets under management spread among its equity (47% of AUM), balanced (5%), fixed-income (22%), alternative investment (14%), and money market (12%) operations. Passive products account for 32% of Invesco's total AUM, including 56% of the company's equity operations and 13% of its fixed-income platform. Invesco's U.S. retail business is one of the 10 largest nonproprietary fund complexes in the country. The firm also has a meaningful presence outside the U.S., with close to one third of its AUM sourced from Canada (2%), the U.K. (4%), continental Europe (11%), and Asia (15%).

Read more on IVZ